Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders (OPTIMAL-DOSE)
Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study
This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Goksu Goc, MD
- Phone Number: +383 49 878 550
- Email: goksu.goc@gmail.com
Study Locations
-
-
-
Pristina, Kosovo, 10000
- American Hospital Kosova
-
Contact:
- Goksu Goc, MD
- Phone Number: +383 49 878 550
- Email: goksu.goc@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.
Description
Inclusion Criteria:
- Woman aged 18 to 42 years.
- Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
- Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
- First eligible (index) cycle during the study period; both ovaries present.
- Written informed consent for data collection and processing.
Exclusion Criteria:
- Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
- Non-antagonist protocol (for example, long GnRH-agonist).
- Oocyte-donation or fertility-preservation (egg-freezing) cycle.
- A prior cycle of the same woman already enrolled in the study.
- Inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Lower starting dose (150 international units [IU] or less)
Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study). |
FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively. |
|
Higher starting dose (more than 150 IU)
Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study). |
FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of mature metaphase II (MII) oocytes retrieved
Time Frame: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total follicle-stimulating hormone (FSH) activity administered
Time Frame: From the first to the last day of ovarian stimulation (up to 21 days)
|
Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Gonadotropin medication cost
Time Frame: From the first to the last day of ovarian stimulation (up to 21 days)
|
Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Total number of oocytes retrieved
Time Frame: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
|
Oocyte maturity rate
Time Frame: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
|
Cycle cancellation before oocyte retrieval
Time Frame: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
|
Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure. |
From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
|
|
Duration of ovarian stimulation
Time Frame: From the first to the last day of ovarian stimulation (up to 21 days)
|
Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Number of normally fertilised oocytes with two pronuclei (2PN)
Time Frame: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
|
Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure. |
At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
|
|
Number of usable embryos
Time Frame: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once. |
Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
|
Number of blastocysts
Time Frame: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure. |
Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Live birth (exploratory)
Time Frame: Up to 12 months after the start of ovarian stimulation
|
Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively. |
Up to 12 months after the start of ovarian stimulation
|
|
Clinical pregnancy (exploratory)
Time Frame: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)
|
Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively. |
At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Infertility
- Infertility, Female
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Peptide Hormones
- Peptides
- Amino Acids, Peptides, and Proteins
- Pituitary Hormones
- Gonadotropins
- Pituitary Hormones, Anterior
- Gonadotropins, Pituitary
- Follicle Stimulating Hormone
Other Study ID Numbers
Other Study ID Numbers
- OPTIMAL-DOSE-OBS-2026-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.